Home » Stocks » VVOS

Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics will go public soon, but the exact IPO date is still unknown.
Stock Price: $5.00 - $7.00
Current IPO price range

Stock Price Chart

Key Info

Market Cap 103.01M
Revenue (ttm) 12.84M
Net Income (ttm) -10.71M
Shares Out 17.17M
EPS (ttm) -0.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

More Stats

Market Cap 103.01M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 17.17M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.62
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield -10.40%
FCF Yield n/a
Payout Ratio n/a
Shares Short n/a
Short Ratio n/a
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 8.02
PB Ratio n/a
Revenue 12.84M
Operating Income n/a
Net Income -10.71M
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin -83.44%
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$n/a*
*No analysts have provided price targets for this stock.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year20192018
Revenue11.393.79
Revenue Growth200.43%-
Net Income / Loss-11.75-9.44
Numbers in millions USD.

Company Profile

Company Details

Full Name Vivos Therapeutics, Inc.
Country United States
Employees 74
CEO R. Kirk Huntsman

Stock Information

Ticker Symbol VVOS
Stock Exchange NASDAQ
Industry Medical Devices
Unique Identifier NASDAQ: VVOS
IPO Date Pending

Description

Vivos Therapeutics is a revenue stage medical technology company focused on the development and commercialization of a highly differentiated technology offering a clinically effective non-surgical, non-invasive, non-pharmaceutical, and low-cost solution for patients with sleep disordered breathing (SDB), including mild-to-moderate obstructive sleep apnea (OSA). We offer novel and proprietary alternatives for treating mild-to-moderate OSA as well as certain craniofacial and anatomical anomalies known to be associated with mild-to-moderate OSA. We believe our products and technology represent a significant improvement in the treatment of mild-to-moderate OSA versus other treatments such as continuous positive airway pressure (or CPAP). Our treatment for mild-to-moderate OSA involves specially designed and customized oral appliances and treatment protocols that we call the Vivos System. We believe the Vivos System technology represents the first non-surgical, non-invasive and cost-effective solution that normally does not require lifetime use or intervention for the hundreds of millions of people globally who suffer from mild-to-moderate OSA. We intend to more rapidly expand the use of the Vivos System by actively recruiting dentists and training them about OSA and the use and application of our products and technology to treat mild-to-moderate OSA.